Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus SCOPOLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus SCOPOLAMINE.
DETROL vs SCOPOLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Scopolamine is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the action of acetylcholine at these receptors in the central nervous system and periphery.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
1.5 mg transdermal patch applied to postauricular skin every 72 hours; for prevention of motion sickness, apply 4-5 hours before exposure. Alternatively, 0.3-0.65 mg intramuscularly or intravenously every 6-8 hours as needed; or 0.4-0.8 mg subcutaneously. Oral dose: 0.4-0.8 mg every 6-8 hours as needed.
None Documented
None Documented
Clinical Note
moderateScopolamine + Venlafaxine
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Venlafaxine."
Clinical Note
moderateScopolamine + Nefazodone
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone."
Clinical Note
moderateScopolamine + Stiripentol
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Stiripentol."
Clinical Note
moderateScopolamine + Fesoterodine
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Terminal elimination half-life is approximately 2–4 hours in adults; in elderly or hepatic impairment, half-life may be prolonged.
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of elimination; biliary/fecal excretion accounts for the remainder.
Category C
Category A/B
Anticholinergic
Anticholinergic
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine."